- Home
- JAZZ vs STLA Comparison
JAZZ vs STLA Comparison
Compare JAZZ & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | STLA |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | Ireland | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 16.9B |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | STLA |
|---|---|---|
| Price | $254.86 | $5.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $217.57 | $11.59 |
| AVG Volume (30 Days) | 789.8K | ★ 18.8M |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 7.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.43 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $7.18 |
| Revenue Next Year | $7.68 | $3.50 |
| P/E Ratio | $54.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $5.25 |
| 52 Week High | $250.49 | $12.22 |
Technical Indicators
Market Signals| Indicator | JAZZ | STLA |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 41.84 |
| Support Level | $222.49 | $5.56 |
| Resistance Level | N/A | $8.30 |
| Average True Range (ATR) | 7.53 | 0.15 |
| MACD | 0.49 | 0.08 |
| Stochastic Oscillator | 99.98 | 66.46 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024, it sold 5.5 million vehicles, 47%, 26%, and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.